What does LL-37 actually do, where is the evidence strongest, and is it ready for clinical use as an antimicrobial peptide?

What LL-37 actually is

LL-37 is the active 37-amino-acid C-terminal fragment of the human cathelicidin protein hCAP18. It's the only cathelicidin-derived antimicrobial peptide produced by humans, and it sits near the top of the innate immune system's first-line defense against bacteria, fungi, and some viruses.

The name comes from the sequence: it begins with two leucine residues (LL) and is 37 amino acids long. It's produced by neutrophils, epithelial cells, and keratinocytes, and its expression is strongly upregulated by active vitamin D (1,25-dihydroxyvitamin D₃). This vitamin-D dependence is one of the better-characterized mechanisms by which vitamin D status influences immune function.

Evidence tier: 2 — biochemistry of LL-37 is well-characterized; clinical-translation evidence is thinner than the mechanism work.

LL-37 has been one of the most-studied antimicrobial peptides since its discovery in the late 1990s. The mechanism is established; clinical translation has been slow because LL-37 has significant translational challenges (immunogenicity, plasma stability, manufacturing cost) that have kept it out of FDA-approved status despite >20 years of preclinical work.

The mechanism

Evidence tier: 2 — well-characterized at the biochemical level.

LL-37 produces antimicrobial and immunomodulatory effects via several mechanisms:

Direct membrane disruption — LL-37 is a cationic amphipathic α-helical peptide. It binds bacterial membranes (which carry net negative charge from lipopolysaccharide or lipoteichoic acid) and disrupts membrane integrity via the "carpet model" or "toroidal pore" mechanism. The cell wall is breached, intracellular contents leak, and the bacterium dies. This mechanism is broad-spectrum (Gram-positive, Gram-negative, fungi, some enveloped viruses) and is harder for organisms to evolve resistance to than small-molecule antibiotics because the target (membrane charge architecture) isn't easily modified.

Biofilm disruption — LL-37 disrupts bacterial biofilms, which is significant because biofilm-embedded organisms are typically 100-1000x more resistant to conventional antibiotics than planktonic organisms. Chronic infections (chronic wounds, dental plaque, cystic fibrosis airway, prosthetic device infections) are biofilm-driven.

Chemotactic activity — LL-37 attracts neutrophils, monocytes, and T-cells to infection sites via FPR2 (formyl peptide receptor 2) signaling. This is an immune-recruitment function distinct from its direct antimicrobial activity.

Immunomodulatory effects — LL-37 modulates Toll-like receptor signaling, dampens excessive LPS-driven inflammation, and influences dendritic cell function. The net effect is "improved immune response quality" rather than simple immune activation.

Wound-healing promotion — LL-37 stimulates keratinocyte migration, angiogenesis, and epithelial-cell proliferation. This is the basis for the chronic-wound-healing applications.

Vitamin D dependence — the VDR gene (vitamin D receptor) directly regulates LL-37 expression. Vitamin D-deficient patients produce less LL-37, which contributes to the increased infection risk observed in vitamin D deficiency.

Where the evidence stands

Evidence tier: 3 — preclinical evidence dominates; human RCT evidence is thin.

Antimicrobial activity (in vitro, animal models) Extensive evidence across bacteria, fungi, and some viruses. LL-37 is active against Staphylococcus aureus (including methicillin-resistant strains), Pseudomonas aeruginosa, Escherichia coli, Candida albicans, and others at micromolar concentrations.

Chronic wound healing (small clinical trials) LL-37 in topical wound-healing formulations has shown benefit in small studies of chronic venous ulcers and diabetic foot ulcers. The 2014 Grönberg et al. trial showed accelerated re-epithelialization vs placebo. Promelin (an LL-37 analog) reached Phase 2 in chronic wound trials.

Atopic dermatitis (mechanism + small-trial evidence) Reduced LL-37 expression has been documented in atopic dermatitis lesions, and supplementation has shown benefit in small studies. The mechanism: AD patients often have impaired cathelicidin response, which contributes to their bacterial-colonization-driven inflammation.

Periodontal disease (preclinical + small clinical) LL-37 in oral formulations has been studied for chronic periodontitis. Real but small evidence base.

Cancer (active research area, no FDA approval) LL-37 has been studied as both pro- and anti-tumorigenic depending on cancer type. The picture is complex — LL-37 promotes some cancers (ovarian, breast) and inhibits others (colon, gastric). This complexity has slowed clinical translation.

Sepsis (mechanism work, no clinical evidence) Plasma LL-37 levels correlate with sepsis outcomes in observational studies, but therapeutic supplementation hasn't reached clinical-trial readiness.

Why translation has been slow

Evidence tier: 3 — well-characterized challenges in the AMP literature.

LL-37 has been "the next antibiotic" since the late 1990s but no LL-37-based drug has reached FDA approval. The reasons:

• Plasma stability: LL-37 is rapidly degraded by proteases in serum, limiting systemic dosing
• Manufacturing cost: a 37-aa peptide is expensive to produce at therapeutic scale
• Immunogenicity concern: foreign-source LL-37 could theoretically trigger anti-cathelicidin immune responses; this hasn't materialized clinically but has slowed development
• Pleiotropic effects: the same molecule that kills bacteria also stimulates wound healing, modulates immune signaling, and has cancer-context-dependent effects — this makes clinical-trial design difficult
• Investor risk-aversion: antimicrobial drug development is famously unprofitable; LL-37 has had multiple stalled commercial programs

The clinical pathways that have advanced fastest: topical formulations for wound healing and skin inflammation, where stability and systemic exposure aren't issues.

The vitamin D connection

Evidence tier: 2 — well-characterized at the molecular level.

LL-37 expression is directly upregulated by active vitamin D (calcitriol) via vitamin D response elements in the cathelicidin gene promoter. Vitamin D-deficient individuals produce meaningfully less LL-37, and this is one of the better-established mechanisms by which vitamin D status influences infection susceptibility.

Clinical implications:

• Maintaining vitamin D sufficiency (typically 30-50 ng/mL serum 25-OH-D) supports endogenous LL-37 production
• Vitamin D supplementation has shown modest benefit in respiratory infection prevention in deficient populations, partly via the LL-37 pathway
• Aggressive vitamin D dosing for "boosting LL-37" is poorly evidenced — once sufficiency is reached, additional vitamin D doesn't proportionally increase LL-37

Maintaining vitamin D sufficiency is the most practical "LL-37 intervention" available to most people. Supplemental LL-37 is a step further that should be reserved for indications where the mechanism warrants it.

Routes and protocols

Evidence tier: 4 — protocol-driven, not strongly evidence-anchored.

LL-37 is not FDA-approved and there are no consensus protocols. What's used in practice:

Topical (wound healing, atopic dermatitis, periodontal use) Concentrations: 0.05-0.5% in cream, ointment, or solution. Applied 1-2x daily to affected area. This is the route with the strongest mechanistic and small-trial evidence.

Subcutaneous (systemic immune modulation, off-label) Doses in the 100-500 µg/day range, typically 5 days on / 2 days off cycles. Less established; protocol-driven.

Nebulized (cystic fibrosis airway research, experimental) Aerosolized LL-37 for biofilm-driven airway infection. Experimental; not in regular clinical use.

Oral — does NOT work. LL-37 is rapidly degraded in the GI tract; there's no PepT1-style uptake for a 37-aa molecule.

The practical floor: if you're using LL-37, source from a compounding pharmacy with COA verification, and start topical unless there's a specific systemic indication.

What LL-37 is not

Evidence tier: 4 — practitioner positioning.

• Not a substitute for conventional antibiotics in acute serious infection. Sepsis, pneumonia, severe skin and soft tissue infections need targeted antibiotic therapy with documented efficacy. LL-37 has no role in acute serious infection at this time.
• Not a general "immune booster" — its mechanism is specific antimicrobial + chronic-wound + chronic-inflammation work
• Not effective orally — molecule is too large + protease-sensitive
• Not without theoretical cancer-context risk — given the pro-tumorigenic data in some cancer types, LL-37 should be avoided in patients with active malignancy without oncology coordination

Safety profile

Evidence tier: 3 — favorable in topical use; less data for systemic.

Topical use: minimal documented adverse events. Mild local irritation occasional.

Systemic use: less data. Theoretical concerns: - Immunogenicity (anti-cathelicidin antibodies — not documented clinically but biologically possible) - Inflammatory cytokine effects at high doses - Cancer-context dependence (avoid in active malignancy) - Plasma stability issues mean dosing predictability is harder than for stable peptides

The practical safety framing: topical LL-37 has a clean profile and reasonable evidence base. Systemic LL-37 is experimental and should be approached cautiously.

Where LL-37 fits in a peptide stack

Evidence tier: 4 — emerging clinician guidance.

LL-37 + BPC-157 (topical wound healing): complementary mechanisms — LL-37 antimicrobial + immune modulation, BPC-157 tissue regeneration + angiogenesis. Reasonable stack for chronic non-healing wounds.

LL-37 + KPV (mucosal inflammation): LL-37 handles the antimicrobial layer, KPV handles the anti-inflammatory layer. Emerging clinical interest; not well-established as a fixed protocol.

LL-37 + Thymosin α-1 (chronic infection adjunct): innate (LL-37) + adaptive (Tα1) immune modulation. Used in some functional-medicine chronic-infection protocols (Lyme, chronic viral); community-driven rather than evidence-anchored.

Vitamin D optimization + LL-37: redundant if vitamin D status is sufficient. If vitamin D-deficient, prioritize vitamin D repletion before supplemental LL-37.

Cost reality

Evidence tier: 4 — observational pricing.

• Topical LL-37 cream (compounding pharmacy): $80-200/month for typical application volume
• SC LL-37 vial (compounding pharmacy): $200-450/month for daily microgram-range protocol
• Research-supplier reagent-grade powder: $80-200 per few-mg quantity (no clinical oversight; pharmaceutical-grade is preferred)
• DIY topical formulation: lower cost but formulation challenges (LL-37 is protease-sensitive and requires specific vehicles for stability)

For a peptide with no FDA approval and limited clinical evidence at scale, costs are meaningful. The topical route is the most cost-effective and has the strongest evidence-to-cost ratio.

What we don't know

Evidence tier: 5 — genuine gaps.

• Whether topical LL-37 for chronic wounds has effect sizes large enough to justify routine use vs standard-of-care wound care
• Long-term safety of SC LL-37 in sustained use
• Whether nebulized LL-37 for cystic fibrosis airway is clinically viable
• Optimal vehicle/formulation for skin penetration without protease degradation
• Whether resistance to LL-37 emerges in clinical use the way it does with conventional antibiotics

Limitations

This is not medical advice. Real limits:

• Not first-line for serious bacterial infection — use evidence-based antibiotics
• Avoid in active malignancy without oncology coordination — pro-tumorigenic in some cancer types
• Don't expect oral efficacy — molecule is degraded in GI tract
• Don't use during pregnancy/nursing without specialist input — limited safety data
• Source from compounding pharmacy with COA verification — quality varies dramatically
• Maintain vitamin D sufficiency first (more evidence-anchored than supplemental LL-37)
• Stop if persistent local or systemic adverse effects occur

The bottom line

LL-37 is the only human cathelicidin antimicrobial peptide and one of the most-studied AMPs in the literature. Its mechanism is genuinely interesting — broad-spectrum antimicrobial, biofilm-disrupting, wound-healing-promoting, vitamin-D-dependent. Its clinical translation has been slow.

The honest 2026 framing: LL-37 has the best evidence for topical chronic-wound healing and possibly atopic dermatitis. It's emerging in chronic-infection-adjunct protocols. It is not yet a substitute for conventional antibiotics, not yet FDA-approved, and not without theoretical risks (cancer context, immunogenicity).

For most users, optimizing vitamin D status produces a meaningful endogenous LL-37 response and is the better intervention. Supplemental LL-37 is a step further reserved for specific indications.

What we'll be tracking

• Phase 2/3 RCT readouts for LL-37 analogs in chronic wound healing
• FDA pathway development (no current sponsor known)
• Long-term safety data from compounding-pharmacy adverse-event reporting
• Resistance pattern emergence in clinical use

For ongoing context, see the Immune & Gut pillar, the KPV peptide deep-dive, the Thymosin α-1 immune modulation article, and the Peptides for IBD/UC protocol guide.

References

• Dürr UH, Sudheendra US, Ramamoorthy A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. PMID 16716251
• Wang G. 2014. Human antimicrobial peptides and proteins. Pharmaceuticals (Basel). PMID 24959605
• Grönberg A, Mahlapuu M, Ståhle M, et al. 2014. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen. PMID 24917415
• Liu PT, Stenger S, Li H, et al. 2006. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. PMID 16497887
• Vandamme D, Landuyt B, Luyten W, Schoofs L. 2012. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. PMID 22325078